Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.

abstract：:During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue. A large multicenter, double-blind, comparative trial of haloperidol decanoate and fluphenazine decanoate has been complet...

journal_title：Clinical neuropharmacology

authors： Cookson JC

更新日期：1991-01-01 00:00:00

abstract：:The capacity of peripheral blood mononuclear cells (PBMCs) of anorexia nervosa (AN) patients to produce interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-3-like activity (IL-3-LA) was studied. A significantly lower (-49%, p < 0.005) capacity to synthesize IL-2 and an almost significantly impaired ability (-3...

journal_title：Clinical neuropharmacology

authors： Bessler H,Karp L,Notti I,Apter A,Tyano S,Djaldetti M,Weizman R

更新日期：1993-06-01 00:00:00

abstract：:Clinical trials with cholinergic agents suggest that cholinergic hypertrophy may be beneficial in the treatment of Alzheimer's disease (AD). Recent findings substantiate the view that nerve growth factor (NGF) selectively acts on cholinergic neurons. In adult rats and primates, intraventricular administration of nerve...

journal_title：Clinical neuropharmacology

authors： Hefti F,Schneider LS

更新日期：1991-01-01 00:00:00

abstract：:Two patients with essential tremor who had no psychiatric history developed symptoms of psychosis (visual hallucinations, paranoia, and vivid dreams) 3 days after starting topiramate (25 mg BID) for tremor control. All adverse symptoms resolved several days after topiramate was discontinued. ...

journal_title：Clinical neuropharmacology

authors： Zesiewicz TA,Tullidge A,Tidwell J,Sullivan KL,Hauser RA

更新日期：2006-05-01 00:00:00

abstract：:We studied the effect of chronic bromocriptine cotherapy on levodopa kinetics in seven patients with Parkinson's disease who were receiving levodopa therapy. Plasma levodopa concentrations were measured after a standard oral levodopa fasting dose over a 5-hour period, on two different sessions, without and with bromoc...

journal_title：Clinical neuropharmacology

authors： Contin M,Riva R,Martinelli P,Albani F,Baruzzi A

更新日期：1992-12-01 00:00:00

abstract：:Transient global amnesia (TGA) has been proposed as a possible adverse effect of sildenafil. There are rare cases in the literature, but none had strong evidence to support. Our case is the first to demonstrate a focal punctate diffusion-weighted imaging lesion at the right hippocampus after the use of sildenafil. Thi...

journal_title：Clinical neuropharmacology

authors： Lin KY,Liu MN,Wang PH,Lau CI

更新日期：2020-03-01 00:00:00

abstract：:Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...

journal_title：Clinical neuropharmacology

authors： Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri S

更新日期：1994-01-01 00:00:00

abstract：:A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. No risk factors for rhabdomyolysis were found, but the calcium-dependent potassium efflux, normally responsible for membrane hyperpolarization and muscle refractoriness, was severely ...

journal_title：Clinical neuropharmacology

authors： Koren W,Koren E,Nacasch N,Ehrenfeld M,Gur H

更新日期：1998-07-01 00:00:00

abstract：:The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

journal_title：Clinical neuropharmacology

authors： Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

更新日期：1994-02-01 00:00:00

abstract：:Daily 20-mg doses of Copolymer 1 have been shown to significantly decrease the relapse rate in patients with multiple sclerosis (MS). In the present open-label study, patients with relapsing MS were treated with the same dose of Copolymer 1 administered on alternate days. Sixty-eight patients were recruited: fifty-one...

journal_title：Clinical neuropharmacology

authors： Flechter S,Kott E,Steiner-Birmanns B,Nisipeanu P,Korczyn AD

更新日期：2002-01-01 00:00:00

abstract：:The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and e...

journal_title：Clinical neuropharmacology

authors： Thalamas C,Rajman I,Kulisevsky J,Lledó A,Mackie AE,Blin O,Gillespie TA,Seger M,Rascol O

更新日期：2005-05-01 00:00:00

abstract：:Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

journal_title：Clinical neuropharmacology

authors： Yasui-Furukori N,Sato Y,Kato H,Kaneko S

更新日期：2012-01-01 00:00:00

abstract：:Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study w...

journal_title：Clinical neuropharmacology

authors： Bagheri H,Damase-Michel C,Lapeyre-Mestre M,Cismondo S,O'Connell D,Senard JM,Rascol O,Montastruc JL

更新日期：1999-07-01 00:00:00

abstract：:Adjunctive use of methylphenidate, a central stimulant, has been considered as a potential therapeutic choice for patients with refractory unipolar depression, geriatric depression, bipolar depression, and depression secondary to a medical illness. We present a case of psychotic unipolar depression in which the patien...

journal_title：Clinical neuropharmacology

authors： Huang CC,Shiah IS,Chen HK,Mao WC,Yeh YW

更新日期：2008-07-01 00:00:00

abstract：:Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

journal_title：Clinical neuropharmacology

authors： Klawans HL,Tanner CM,Barr A

更新日期：1984-01-01 00:00:00

abstract：BACKGROUND:We investigated the frequencies of the symptoms such as "ataxia, depression, insomnia, anorexia, and pain," that have been reported to be associated with 5-HT1A receptor, and the effect of tandospirone citrate (tandospirone: 5-HT1A agonist) in patients with Machado-Joseph disease (MJD). METHODS:Ten MJD pati...

journal_title：Clinical neuropharmacology

authors： Takei A,Fukazawa T,Hamada T,Sohma H,Yabe I,Sasaki H,Tashiro K

更新日期：2004-01-01 00:00:00

abstract：:Acute psychotic episodes represent critical situations during the course of schizophrenia. Olanzapine (OLZ), a second-generation antipsychotic, is efficacious in acute settings at dosages of 5 to 20 mg/d, and it can be considered a first-line treatment for patients with an acute episode of schizophrenia. The aim of th...

journal_title：Clinical neuropharmacology

authors： Mauri MC,Colasanti A,Rossattini M,Moliterno D,Baldi ML,Papa P

更新日期：2006-05-01 00:00:00

abstract：:The selective estrogen receptor modulator, tamoxifen, is extensively used for the endocrine treatment of all stages of hormone receptor-positive breast cancer. Tamoxifen is a mainly inactive prodrug, necessitating metabolism by the cytochrome P450 (CYP450) pathway, predominantly the Cytochrome P450 2D6 (CYP2D6), into ...

journal_title：Clinical neuropharmacology

authors： De Berardis D,Brucchi M,Serroni N,Valchera A,Fornaro M,Mazza M,Martinotti G,Di Giannantonio M

更新日期：2014-01-01 00:00:00

abstract：:Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatme...

journal_title：Clinical neuropharmacology

authors： Quagliato EM,Carelli EF,Viana MA

更新日期：2010-01-01 00:00:00

abstract：:Modafinil is a psychostimulant compound that is just now becoming available in many countries for treatment of narcoleptic and hypersomnic patients. Whereas sleep attacks and drowsiness can be effectively improved, the drug does not sufficiently reduce cataplectic seizures. It therefore is often used in combination wi...

journal_title：Clinical neuropharmacology

authors： Grözinger M,Härtter S,Hiemke C,Griese EU,Röschke J

更新日期：1998-03-01 00:00:00

abstract：:A correlation was found among the degree of memory loss, intellectual impairment, the quantity of senile plaques, and a decrease in choline acetyltransferase and acetylcholinesterase activity in patients affected by senile dementia of the Alzheimer type. In this study, patients were subjected to a series of computeriz...

journal_title：Clinical neuropharmacology

authors： Agnoli A,Martucci N,Manna V,Conti L,Fioravanti M

更新日期：1983-01-01 00:00:00

abstract：:In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably a...

journal_title：Clinical neuropharmacology

authors： Fabre LF

更新日期：1989-01-01 00:00:00

abstract：:Recent studies have suggested that deprenyl may exert a neuroprotective influence and thus retard progression of Parkinson's disease (PD). On the other hand, the data do not disprove that deprenyl is primarily another form of symptomatic therapy like levodopa. Longitudinal Gompertzian analysis demonstrates the absence...

journal_title：Clinical neuropharmacology

authors： Riggs JE

更新日期：1991-12-01 00:00:00

abstract：:Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

journal_title：Clinical neuropharmacology

authors： Giménez-Roldán S,Esteban EM,Mateo D

更新日期：2001-11-01 00:00:00

abstract：:We studied the effectiveness of OR-611 and OR-462, two novel inhibitors of the enzyme catechol-O-methyltransferase (COMT), on 3-O-methyldopa (OMD) formation in cynomolgus monkeys following intravenous levodopa administration. OR-611 dose-dependently reduced the area under the OMD concentration-vs-time curve, reduced m...

journal_title：Clinical neuropharmacology

authors： Cedarbaum JM,Leger G,Guttman M

更新日期：1991-08-01 00:00:00

abstract：:This article outlines the reasons that detection of subtle changes in the cognitive system is difficult in geriatric assessment. A new assessment approach is introduced that examines cognitive patterns and facilitates the evaluation of subtle changes. ...

journal_title：Clinical neuropharmacology

authors： Poon LW

更新日期：1993-01-01 00:00:00

abstract：:Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage ...

journal_title：Clinical neuropharmacology

authors： Nagayama H,Hamamoto M,Ueda M,Nito C,Yamaguchi H,Katayama Y

更新日期：2004-11-01 00:00:00

abstract：:The pyrimidine nucleosides uridine (URI) and cytidine (CYT), alone or associated with n-acetyl-glutamine (NAG), were injected acutely or subchronically to aged (26 months old) male rats of the Sprague-Dawley strain. Learning and memory abilities of the animals were studied with tests of avoidance behavior. The acquisi...

journal_title：Clinical neuropharmacology

authors： Drago F,D'Agata V,Valerio C,Spadaro F,Raffaele R,Nardo L,Grassi M,Freni V

更新日期：1990-08-01 00:00:00

abstract：:The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...

journal_title：Clinical neuropharmacology

authors： Thomas A,Iacono D,Bonanni L,D'Andreamatteo G,Onofrj M

更新日期：2001-01-01 00:00:00

abstract：:Oxidant stress resulting from excess dopamine (DA) may contribute to the development and progression of Parkinson's disease (PD). Free radicals resulting from the enzymatic metabolism of DA are most often discussed in this regard. However, levodopa (L-DOPA) and DA can also undergo autooxidation, producing free radical...

journal_title：Clinical neuropharmacology

authors： Ling ZD,Pieri SC,Carvey PM

更新日期：1996-08-01 00:00:00